


Nedosiran Clinical Development Program – as of 10 Sep 2024



Expanded Access

Expanded Access Treatment Protocol – PH1¹⁰
On-label nedosiran treatment protocol in patients (aged 6 years and older) with PH1 and relatively intact renal function not satisfactorily treated with current SoC
Estimated N = 10

Abbreviations: ESKD=end-stage kidney disease; Uox=urinary oxalate, PH=primary hyperoxaluria, N=number, SoC = standard of care, † = PH3 patient enrollment not open in the US
References: 1. Hoppe B, et al. *Kidney Int.* 2022;101(3):626-634. 2. ClinicalTrials.gov identifier: NCT03392896. Accessed March 9, 2023. 3. ClinicalTrials.gov identifier: NCT03847909. <https://www.clinicaltrials.gov/ct2/show/record/NCT03847909>. Updated July 30, 2021. Accessed May 20, 2022. 4. Baum MA, Langman C, Cochat P, et al. *Kidney Int.* 2023;103(1):207-217. 5. ClinicalTrials.gov identifier: NCT04042402. <https://www.clinicaltrials.gov/ct2/show/study/NCT04042402>. Updated July 16, 2021. Accessed May 20, 2022. 6. ClinicalTrials.gov identifier: NCT04555486. <https://www.clinicaltrials.gov/ct2/show/study/NCT04555486>. Updated September 10, 2021. Accessed May 23, 2022. 7. News release, Business Wire; October 19, 2021. <https://dicerna.com/wp-content/uploads/2022/04/Dicerna-Announces-Results-for-PHYOX™4-Single-Dose-Study-of-Nedosiran-in-Primary-Hyperoxaluria-Type-3-PH3.pdf>. Accessed May 23, 2022. 8. ClinicalTrials.gov identifier: NCT04580420. <https://www.clinicaltrials.gov/ct2/show/study/NCT04580420>. Updated July 8, 2021. Accessed May 20, 2022. 9. ClinicalTrials.gov identifier: NCT05001269. <https://www.clinicaltrials.gov/ct2/show/study/NCT05001269>. Updated September 10, 2021. Accessed May 20, 2022. 10. ClinicalTrials.gov identifier: NCT05993416. <https://www.clinicaltrials.gov/ct2/show/study/NCT05993416>. Accessed August 1, 2023.